	US 11,723,905 B2
	Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
George P. Luke, Clinton, CT (US); and Pratik Sheth, Watertown, MA (US)
Assigned to FORMA Therapeutics, Inc., Watertown, MA (US)
Filed by FORMA Therapeutics, Inc., Watertown, MA (US)
Filed on Feb. 24, 2021, as Appl. No. 17/183,606.
Application 17/183,606 is a continuation of application No. 16/693,642, filed on Nov. 25, 2019, granted, now 10,959,994.
Application 16/693,642 is a continuation of application No. 16/414,716, filed on May 16, 2019, granted, now 10,532,047, issued on Jan. 14, 2020.
Claims priority of provisional application 62/692,591, filed on Jun. 29, 2018.
Claims priority of provisional application 62/672,461, filed on May 16, 2018.
Claims priority of provisional application 62/672,462, filed on May 16, 2018.
Prior Publication US 2021/0177829 A1, Jun. 17, 2021
Int. Cl. A61K 31/4709 (2006.01); A61K 9/00 (2006.01); A61K 47/12 (2006.01); A61K 47/38 (2006.01)

CPC A61K 31/4709 (2013.01) [A61K 9/0053 (2013.01); A61K 47/12 (2013.01); A61K 47/38 (2013.01)]

27 Claims

1. An olutasidenib oral unit dosage form comprising olutasidenib in a crystalline form, and having a total of 150 mg olutasidenib in the unit dosage form.